Search

Scott M Whitcup

from Irvine, CA
Age ~65
Get Report
Also known as:
Scott Dr Whitcup, Scott Ppty Whitcup, Scott M Whiteup
Related to:
Tamra A Simulick, 46Graham Rempel, 42Michael Bradford, 45Orlando BruniSteven Johnson, 52Marian Painchaud, 68
Connected to:
Aaliyah S White, 27Adriana B White, 39Aftaan M White, 43Ahmed A White, 54Alba Y White, 51Albert White, 34Alburn A White, 65Aleia M White, 44Alfie White, 34Alica C White, 70

Scott Whitcup Phones & Addresses

  • Irvine, CA
  • 27591 Lost Trail Dr, Laguna Hills, CA 92653 (714) 346-0000
  • 7702 Sargent Ct, Potomac, MD 20854
  • Rockville, MD
  • 363 White Cap Ln, Newport Coast, CA 92657
  • Boston, MA
  • 27591 Lost Trail Dr, Laguna Hills, CA 92653

Work

Company: ALLERGAN PHARMACEUTICAL Address: 2525 Dupont Dr, Irvine, CA 92612 Phones: (949) 250-1786

Education

School / High School: Weill Cornell Medical College 1984

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Internal Medicine, 1987

Specialities

Internal Medicine • Ophthalmology

Professional Records

Medicine Doctors

Scott Whitcup Photo 1

Dr. Scott M Whitcup, Los Angeles CA - MD (Doctor of Medicine)

View page
Specialties:
Internal Medicine
Ophthalmology
Address:
924 Westwood Blvd Suite 900, Los Angeles, CA 90024
(310) 794-8111 (Phone), (310) 794-0675 (Fax)

ALLERGAN PHARMACEUTICAL
2525 Dupont Dr, Irvine, CA 92612
(949) 250-1786 (Phone)
Certifications:
Internal Medicine, 1987
Ophthalmology, 1991
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Weill Cornell Medical College
Graduated: 1984
Medical School
UCLA Med Ctr
Graduated: 1984
Medical School
Mass Eye Ear-Harvard
Graduated: 1984
Medical School
National Institutes Of Health Clinical Center
Graduated: 1984
Scott Whitcup Photo 2

Scott Michael Whitcup

View page
Specialties:
Internal Medicine
Ophthalmology
Education:
Cornell University (1984)

Resumes

Resumes

Scott Whitcup Photo 3

Founder And Chief Executive Officer

View page
Location:
Orange, CA
Industry:
Pharmaceuticals
Work:
Akrivista and Whitecap Biosciences
Founder and Chief Executive Officer
Allergan 2004 - 2015
Evp, R and D
Allergan 2000 - 2004
Head, Ophthalmology Therapeutic Area
National Eye Institute (Nei) 1993 - 2000
Clinical Director
National Eye Institute (Nei) 1990 - 1992
Clinical Fellow
Education:
Cornell University Medical College 1991 - 1994
Doctor of Medicine, Doctorates Cornell University Medical College 1980 - 1984
Doctor of Medicine, Doctorates Cornell University 1976 - 1980
Bachelors, Bachelor of Arts, Biology
Skills:
Clinical Development
Pharmaceutical Industry
Clinical Research
Medical Affairs
Fda
Medical Devices
Clinical Trials
Ophthalmology
Immunology
Dermatology
R&D
Drug Development
Internal Medicine
Surgery
Oncology
Regulatory Submissions
Urology
Cro
Ctms
Neurology
Gcp
Therapeutic Areas
Infectious Diseases
Languages:
Spanish
Scott Whitcup Photo 4

Scott Whitcup

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Scott M. Whitcup
Vice President, VP-Research and Deve
Allergan Sales, LLC
Manufacture Sales and Distribution Fo Ey · Manufacturer Sales and Distribution of E · Whol Drugs/Sundries · Pharmaceutical Analysis & Microbiology
2525 Dupont Dr, Irvine, CA 92612
(714) 246-4500
Scott M Whitcup
Vice Presi
INAMED, LLC
211 E 7 St STE 620, Austin, TX 78701
2525 Dupont Dr, Irvine, CA 92612
Scott Michael Whitcup
Scott Whitcup MD
Ophthalmology · Internist
2525 Dupont Dr, Irvine, CA 92612
(714) 246-4405
Scott M. Whitcup
Vice president
LIRIS BIOMEDICAL, INC
Business Consulting Services
99 Hayden Ave, Lexington, MA 02421
6 Gill St, Woburn, MA 01801
2525 Dupont Dr, Irvine, CA 92612
(781) 676-7750, (781) 281-0173

Publications

Us Patents

Treating Neurological Disorders Using Selective Antagonists Of Persistent Sodium Current

View page
US Patent:
7060723, Jun 13, 2006
Filed:
Aug 27, 2004
Appl. No.:
10/928949
Inventors:
George R. Ehring - Huntington Beach CA, US
Joseph S. Adorante - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Thomas Malone - Irvine CA, US
Scott M. Whitcup - Laguna Hills CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A01N 43/06
A61K 31/38
US Classification:
514438, 514443, 514448
Abstract:
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.

Treating Neurological Disorders Using Selective Antagonists Of Persistent Sodium Current

View page
US Patent:
7705055, Apr 27, 2010
Filed:
Jan 5, 2006
Appl. No.:
11/326036
Inventors:
George R. Ehring - Huntington Beach CA, US
Joseph S. Adorante - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Thomas Malone - Irvine CA, US
Scott M. Whitcup - Laguna Hills CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 31/12
A01N 35/00
A01N 33/18
A01N 33/24
US Classification:
514678, 514679, 514675, 514676
Abstract:
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.

Treating Neurological Disorders Using Selective Antagonists Of Persistent Sodium Current

View page
US Patent:
7728034, Jun 1, 2010
Filed:
Jan 5, 2006
Appl. No.:
11/326264
Inventors:
George R. Ehring - Huntington Beach CA, US
Joseph S. Adorante - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Thomas Malone - Irvine CA, US
Scott M. Whitcup - Laguna Hills CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A01N 37/00
A61K 31/21
A01N 37/18
A61K 31/16
A01N 35/00
A61K 31/12
US Classification:
514506, 514510, 514613, 514675, 514678, 514679, 514680
Abstract:
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.

Combination Therapy For Glaucoma Treatment

View page
US Patent:
7872045, Jan 18, 2011
Filed:
May 16, 2005
Appl. No.:
11/130863
Inventors:
Robert M. Burk - Laguna Beach CA, US
Mark Holoboski - Laguna Niguel CA, US
Scott M. Whitcup - Laguna Hills CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 31/215
A61K 31/695
US Classification:
514530, 514 63
Abstract:
A method is disclosed herein comprising administering a compound and a second drug to an eye of a mammal for the treatment of glaucoma or the reduction of intraocular pressure, said compound represented by the general formula I;.

Methods Of Preventing And Reducing The Severity Of Stress-Associated Conditions

View page
US Patent:
7977335, Jul 12, 2011
Filed:
May 2, 2008
Appl. No.:
12/114727
Inventors:
Daniel W. Gil - Corona Del Mar CA, US
Scott Whitcup - Laguna Hills CA, US
Mitchell F. Brin - Newport Beach CA, US
John E. Donello - Dana Point CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 31/198
US Classification:
514249
Abstract:
The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.

Treating Neurological Disorders Using Selective Antagonists Of Persistent Sodium Current

View page
US Patent:
8124612, Feb 28, 2012
Filed:
Jan 5, 2006
Appl. No.:
11/326263
Inventors:
George R. Ehring - Huntington Beach CA, US
Joseph S. Adorante - Irvine CA, US
Larry A. Wheeler - Irvine CA, US
Thomas Malone - Irvine CA, US
Scott M. Whitcup - Laguna Hills CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A01N 43/40
A01N 43/82
A61K 31/435
A61K 31/44
A61K 31/41
US Classification:
514277, 514340, 514364
Abstract:
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.

Methods For Treating A Posterior Segment Of An Eye

View page
US Patent:
8569272, Oct 29, 2013
Filed:
Jul 11, 2008
Appl. No.:
12/172194
Inventors:
Robert T. Lyons - Laguna Hills CA, US
James N. Chang - Newport Beach CA, US
John T. Trogden - Anaheim CA, US
Scott M. Whitcup - Laguna Hills CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A01N 45/00
A61F 2/00
A61K 9/14
A61K 33/32
US Classification:
514169, 424427, 424489, 424643
Abstract:
Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0. 1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.

Method For Determining Optimum Intraocular Locations For Drug Delivery Systems

View page
US Patent:
8571802, Oct 29, 2013
Filed:
Nov 30, 2007
Appl. No.:
11/948411
Inventors:
Michael R. Robinson - Irvine CA, US
Devin F. Welty - Foothill Ranch CA, US
Scott M. Whitcup - Laguna Hills CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
G01N 33/50
US Classification:
702 19
Abstract:
A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.

Isbn (Books And Publications)

Uveitis: Fundamentals and Clinical Practice

View page
Author

Scott M. Whitcup

ISBN #

0323022375

Advances in Ocular Immunology: Proceedings of the 6th International Symposium on the Immunology and Immunopathology of the Eye, Bethesda, USA

View page
Author

Scott M. Whitcup

ISBN #

0444817425

Uveitis: Fundamentals and Clinical Practice

View page
Author

Scott M. Whitcup

ISBN #

0815164467

Control profile
Scott M Whitcup from Irvine, CA, age ~65 Get Report